ADMA Biologics Inc ADMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
-
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
-
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
-
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
-
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
-
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
-
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
-
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Trading Information
- Previous Close Price
- $9.72
- Day Range
- $9.62–10.19
- 52-Week Range
- $7.21–20.46
- Bid/Ask
- $10.00 / $10.20
- Shares Outstanding
- 223.98M
- Market Cap
- $2.26B
- Volume/Avg
- 4M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 14.00
- Price/Sales
- 4.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.41%
Company Profile
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 647
- Website
- https://www.admabiologics.com
Valuation
|
Metric
|
ADMA
|
|---|---|
Price/Earnings (Normalized) | 14.00 |
Price/Book Value | 5.59 |
Price/Sales | 4.74 |
Price/Cash Flow | 11.92 |
Price/Earnings
ADMA
Financial Strength
|
Metric
|
ADMA
|
|---|---|
Quick Ratio | 3.62 |
Current Ratio | 6.97 |
Interest Coverage | 25.17 |
Quick Ratio
ADMA
Profitability
|
Metric
|
ADMA
|
|---|---|
Return on Assets (Normalized) | 27.60% |
Return on Equity (Normalized) | 40.64% |
Return on Invested Capital (Normalized) | 31.79% |
Return on Assets
ADMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G!Ym@<? | LOCK|bf^P# | $128B | |||
| Moderna Inc
MRNA
| LOCK|x?@#dpN | LOCK|<P! | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|b$HHSDt | LOCK|b<QWr | $75B | |||
| argenx SE ADR
ARGX
| LOCK|^Pk<F% | LOCK|!k? | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Gkjn>gz | LOCK|sbZ | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Pz%Jr>Q | LOCK|Nw$bk | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Ws?z<bmF | LOCK|#Tg% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|w>pnvdF | LOCK|T^^ | $25B | |||
| Incyte Corp
INCY
| LOCK|yN@$nzs | LOCK|fq | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|lh>Y%<b | LOCK|Lr | $15B |
United States